Search

Displaying results 8311 - 8320 of 8415 in total
  1. Drug

    Nicotinamide adenine dinucleotide phosphate

    go.drugbank.com/drugs/DB03461
    Experimental

    It serves as an electron carrier in a number of reactions, being alternately oxidized (NADP+) and reduced (NADPH). (Dorland, 27th ed)

  2. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety.

  3. Drug

    Luveltamab tazevibulin

    go.drugbank.com/drugs/DB17563
    Investigational

    Luveltamab tazevibulin, formerly known as STRO-002, is novel homogeneous folate receptor alpha (FolRα) targeting antibody-drug conjugate.

  4. Drug

    Tividenofusp alfa

    go.drugbank.com/drugs/DB17628
    ApprovedInvestigational

    Tividenofusp alfa is a first-in-class, brain-penetrant enzyme replacement therapy (ERT) indicated for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome [L56097, L56099

  5. Drug

    Methoxy arachidonyl fluorophosphonate

    go.drugbank.com/drugs/DB02465
    Experimental

    Methoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases.

  6. Drug

    Prolectin-M

    go.drugbank.com/drugs/DB16521
    Investigational

    Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin.

  7. Drug

    Cetrelimab

    go.drugbank.com/drugs/DB15421
    Investigational

    investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as

  8. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as

  9. Drug

    COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

    go.drugbank.com/drugs/DB15845
    Experimental

    As of July 2020, Medicine Invention Design, Inc. is sponsoring a small, controlled clinical trial for the COVID-19 AP TP Vaccine for ‘proof of concept.’

  10. Drug

    Lumicitabine

    go.drugbank.com/drugs/DB14808
    Investigational

    Lumicitabine is under investigation in clinical trial NCT03010059 (A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and